FDA slaps a partial hold on one of AstraZeneca's crucial durvalumab programs
Shares of AstraZeneca $AZN started to slide this morning as the pharma giant confirmed that the FDA has placed a partial clinical hold on a Phase III research program involving its checkpoint inhibitor durvalumab, halting new enrollment.
The partial hold was instituted after investigators tracked bleeding events in a Phase III combo study for durvalumab, its top investigational drug, with tremelimumab for head and neck cancer. But the company cautions that all other studies are proceeding as planned, noting that such bleeding events are not unusual in head and neck cancer.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.